Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus R-CHOP in DLBCL with TP53 mutation and PD-L1 positive
NCT04023916Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Dec 2019
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of sintilimab in diffuse large B-cell lymphoma (DLBCL), sponsored by Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
sintilimab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04023916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04023916.